Literature DB >> 21989351

Pathologic characteristics of pediatric intracranial pilocytic astrocytomas and their impact on outcome in 3 countries: a multi-institutional study.

Tarik Tihan1, Ayca Ersen, Ibrahim Qaddoumi, Maher A Sughayer, Sahsine Tolunay, Maysa Al-Hussaini, Joanna Phillips, Nalin Gupta, Patricia Goldhoff, Anu Baneerjee.   

Abstract

Pilocytic astrocytoma (PA) is one of the most common glial neoplasms in the pediatric population, and its gross total resection can be curative. Treatment of partially resected or recurrent tumors is challenging, and the factors associated with increased recurrence risk are not well defined. Identification of favorable and unfavorable factors can lead to a better understanding and management of patients with PA. We studied the pathologic characteristics of 116 intracranial PAs from 4 institutions representing 3 distinct geographic regions to identify factors that may be associated with biological behavior. The study included 65 boys and 51 girls with a median age of 6 years. Median follow-up for all patients was 101 months, during which time 38 patients had recurrence. Progression-free and overall survivals were better in patients who underwent gross total resection. We were not able to identify any differences in pathologic and molecular markers among the 4 institutions from 3 different countries. However, progression-free survival varied significantly among institutions. Sox-2 was the most prevalent stem cell marker in PA, and many tumors showed synaptophysin positivity. BRAF immunostaining was not useful in determining BRAF duplication. BRAF duplication was more typical of posterior fossa tumors. There was a strong correlation between BRAF duplication and pERK immunostaining, suggesting that the RAF/MEK/ERK pathway is active in these tumors. This finding has significant implications given its role in oncogen-induced senescence and possible influence on treatment decisions of subtotally resected tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21989351     DOI: 10.1097/PAS.0b013e3182329480

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  15 in total

1.  Spontaneous modifications of contrast enhancement in childhood non-cerebellar pilocytic astrocytomas.

Authors:  Simona Gaudino; Francesca Quaglio; Chiara Schiarelli; Matia Martucci; Tommaso Tartaglione; Maria Rosaria Gualano; Giuseppe Maria Di Lella; Cesare Colosimo
Journal:  Neuroradiology       Date:  2012-09       Impact factor: 2.804

Review 2.  The evolving molecular genetics of low-grade glioma.

Authors:  Sriram Venneti; Jason T Huse
Journal:  Adv Anat Pathol       Date:  2015-03       Impact factor: 3.875

Review 3.  To BRAF or not to BRAF: is that even a question anymore?

Authors:  Craig Horbinski
Journal:  J Neuropathol Exp Neurol       Date:  2013-01       Impact factor: 3.685

4.  Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.

Authors:  Craig Horbinski; Marina N Nikiforova; Jill M Hagenkord; Ronald L Hamilton; Ian F Pollack
Journal:  Neuro Oncol       Date:  2012-04-05       Impact factor: 12.300

5.  Insulin-like growth factor 2 mRNA binding protein 3 expression is an independent prognostic factor in pediatric pilocytic and pilomyxoid astrocytoma.

Authors:  Valerie N Barton; Andrew M Donson; Diane K Birks; Bette K Kleinschmidt-DeMasters; Michael H Handler; Nicholas K Foreman; Sarah Z Rush
Journal:  J Neuropathol Exp Neurol       Date:  2013-05       Impact factor: 3.685

6.  Something old and something new about molecular diagnostics in gliomas.

Authors:  Craig Horbinski
Journal:  Surg Pathol Clin       Date:  2012-12-01

7.  BRAF alterations in pediatric low grade gliomas and mixed neuronal-glial tumors.

Authors:  Efthymios Dimitriadis; George A Alexiou; Panagiota Tsotsou; Efthymia Simeonidi; Kalliopi Stefanaki; Amalia Patereli; Neofytos Prodromou; Nikolaos Pandis
Journal:  J Neurooncol       Date:  2013-04-24       Impact factor: 4.130

Review 8.  Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science.

Authors:  Fred H Hochberg; Nadia A Atai; David Gonda; Michael S Hughes; Brolin Mawejje; Leonora Balaj; Robert S Carter
Journal:  Expert Rev Mol Diagn       Date:  2014-05       Impact factor: 5.225

Review 9.  Pathological and molecular advances in pediatric low-grade astrocytoma.

Authors:  Fausto J Rodriguez; Kah Suan Lim; Daniel Bowers; Charles G Eberhart
Journal:  Annu Rev Pathol       Date:  2012-10-29       Impact factor: 23.472

10.  Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma.

Authors:  Sandy Mercurio; Laetitia Padovani; Carole Colin; Manon Carré; Aurélie Tchoghandjian; Didier Scavarda; Sally Lambert; Nathalie Baeza-Kallee; Carla Fernandez; Céline Chappé; Nicolas André; Dominique Figarella-Branger
Journal:  Acta Neuropathol Commun       Date:  2013-05-20       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.